Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab consolidation in non-pCR esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy and R0 surgery
ChiCTR2200060318Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in Esophageal Squamous Cell Carcinoma (ESCC) comparing Sintilimab consolidation with Observation (2 arms). Primary endpoint: Disease-free survival. Planned start May 2022; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2200060318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060318.